Business Context and Reporting Period
The provided filing is NeuroBo Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2023; it does not identify “Metavia Inc.” The company is a clinical-stage biotechnology business focused on cardiometabolic diseases. Its principal programs are DA-1241 for NASH and type 2 diabetes and DA-1726 for obesity and potentially NASH. The company has not generated product revenue.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $2.4 million | $3.0 million |
| General and administrative expense | $1.4 million | $3.3 million |
| Total operating expenses | $3.8 million | $6.3 million |
| Net loss | $0.7 million | $3.3 million |
| Net loss per share | $0.02 | $0.08 |
| Cash flow from operating activities | Not separately provided | $(4.6) million |
At June 30, 2023, cash was $28.7 million, compared with $33.4 million at December 31, 2022. Total assets were $29.2 million and stockholders’ equity was $25.2 million. Current liabilities were $4.0 million, including $1.0 million of warrant liabilities and $2.0 million of accrued liabilities. No debt is reported on the balance sheet.
The company reported an accumulated deficit of $99.1 million. Cash used in investing activities was $4,000, cash used in financing activities was $80,000, and the net decrease in cash was $4.7 million during the six months ended June 30, 2023.
Material Changes Versus the Prior Comparable Period
- Second-quarter R&D expense increased $1.4 million, or approximately 141%, primarily due to DA-1241 drug manufacturing and toxicology work ahead of the planned Phase 2a trial.
- Six-month R&D expense increased $1.1 million, while general and administrative expense decreased $0.9 million.
- Second-quarter net loss improved to $0.7 million from $3.3 million; the six-month net loss improved to $3.3 million from $6.2 million.
- The improvement in net loss was materially affected by non-cash gains from changes in the fair value of warrant liabilities: $3.1 million in the quarter and $3.0 million year to date.
- Warrant liabilities declined from $10.8 million at December 31, 2022 to $1.0 million at June 30, 2023. Warrant exercises resulted in the issuance of approximately 12.8 million common shares during the first six months.
- Common shares outstanding increased from 25.4 million at December 31, 2022 to 38.2 million at June 30, 2023, creating substantial potential dilution relative to the prior period.
- The company discontinued clinical development of ANA001 and COVID-19-related gemcabene development in June 2023 and liquidated its former South Korean subsidiary.
Guidance, Outlook, Risks and Unusual Items
- The FDA cleared the DA-1241 IND in May 2023; management intended to initiate a Phase 2a study in the third quarter of 2023.
- Management intended to file a DA-1726 IND and initiate Phase 1 clinical trials in the second half of 2023.
- Management estimated that existing cash would fund operations into the third quarter of 2024, but stated that additional financing will be required thereafter and that no financing commitment had been secured.
- The financial statements include a going-concern warning. Continued losses and negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern.
- Potential funding sources include equity offerings, debt financing, collaborations, licenses and other arrangements. Equity financing could significantly dilute existing stockholders, while debt financing could impose restrictive covenants.
- The company has substantial contingent license and milestone obligations, including up to $316 million of regulatory milestones under the Dong-A license agreement, plus commercial milestones and single-digit royalties. No such payments were accrued because the milestones were not considered probable.
- Internal controls over financial reporting were not effective due to material weaknesses involving segregation of duties, system access, and supervision and review of financial reporting. Remediation was in process but had not been completed.
Most Important Facts for Investors to Verify
- Confirm the issuer identity, because the supplied filing is for NeuroBo Pharmaceuticals, Inc., not Metavia Inc.
- Verify the timing, enrollment, endpoints, costs and results of the planned DA-1241 Phase 2a trial.
- Track whether the DA-1726 IND was filed and whether Phase 1 trials began as planned.
- Assess the company’s financing capacity, cash runway and terms of any subsequent equity or debt financing.
- Review warrant exercises, remaining warrant liabilities and potential dilution from outstanding warrants and options.
- Monitor remediation of the disclosed material weaknesses in internal controls.
- Review the status and potential financial impact of the Dong-A license, shared-services arrangements and other contingent milestone obligations.